Availability Alerts
Isotope Availability March 2020
The DOE Isotope Program (DOE IP) is pleased to announce the following isotopes are available for purchase currently or in the coming weeks. Don't miss your chance to request a quote and receive this limited material.
New Isotope Availability: Americium-241
The DOE Isotope Program (DOE IP) is pleased to announce the restart of routine production and availability of americium-241 (Am-241) in the United States.
New Batch of Strontium-89 Available Soon
A new batch of strontium-89 (Sr-89) will be available through the DOE Isotope Program (DOE IP) in March 2020.
Selenium-75 Available Soon
The DOE Isotope Program inventory of selenium-75 (Se-75), will soon be replenished and available for purchase i
Tungsten-188 Available in January 2020
The DOE Isotope Program inventory of tungsten-188 (W-188) will soon be replenished and available for purchase in late January 2020.
Copper-67 Available in January 2020
A new batch of high-specific activity copper-67 (Cu-67) will be ready to ship through the DOE Isotope Program on January 22, 2020.
Routine Production of High Specific Activity Cu-67!
This dual-purpose radioisotope has garnered considerable attention in the medical community for its “theranostic” properties, meaning it has emissions suitable for both diagnostic imaging and targeted cancer therapy.
New Batches of Zirconium-88 and Yttrium-88 Available Soon
The DOE IP inventory of radioactive isotopes zirconium-88 (Zr-88) and yttrium-88 (Y-88)
New Batch of Actinium-225 Available in November
A new batch of accelerator-produced actinium-225 (Ac-225) will be available through the U.S. Department of Energy Isotope Program (DOE IP) in mid-November 2019.
Actinium-225 Available in June
A new batch of accelerator-produced actinium-225 (Ac-225) will be available through the U.S. Department of Energy Isotope Program (DOE IP) in mid to late June 2019. This alpha-emitting radionuclide and its decay product bismuth-213 (Bi-213), from an Ac-225/Bi-213 generator, has gained considerable interest within the medical community for their radioimmunotherapy applications.
